Phase 2b study of tamibarotene for the treatment of advanced non-small-cell lung cancer (NSCLC)

CytRx announced that it is initiating a Phase 2b trial with tamibarotene in combination with paclitaxel plus carboplatin for the treatment of patients with advanced non-small-cell lung cancer (NSCLC). In this trial, patients with stage IIIB or IV NSCLC will be treated with up to six cycles of paclitaxel plus carboplatin and either tamibarotene or placebo. The primary objective of the clinical trial is to determine the objective response rate (complete and partial responses) and progression-free survival. Secondarily, the study will evaluate overall survival, quality-of-life and the pharmacokinetics of tamibarotene in this population. The clinical trial, which is expected to enroll approximately 140 patients, will be conducted in several clinical sites in the U.S. and Mexico.

Tamibarotene is an orally available, rationally designed, synthetic retinoid compound.

For more information call (310) 826-5648 or visit www.cytrx.com.